Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Casein kinase I alpha (CKIα) ablation activates p53, and its degradation is key to lenalidomide's efficacy in pre-leukemia.
• Acute myeloid leukemia (AML) is driven by oncogenes regulated by super-enhancers (SEs).

Purpose of the Study:

• To develop novel inhibitors targeting CKIα, CDK7, and CDK9 for enhanced anti-leukemic activity.
• To investigate the mechanism of action of these inhibitors on SEs and p53 activation in AML.

Main Methods:

• Development of dual inhibitors targeting CKIα and transcriptional kinases CDK7/9.
• Analysis of SEs in primary mouse AML cells and patient-derived xenografts.
• Assessment of p53 stabilization, gene transcription suppression, and apoptosis induction.
• Evaluation of therapeutic efficacy in AML mouse models and xenografts.

Main Results:

• The developed inhibitors co-target CKIα, CDK7, and CDK9, augmenting p53 activation.
• Inhibitors abolish newly gained SEs in AML cells and suppress SE-driven oncogene transcription.
• Combined inhibition synergistically stabilizes p53, induces apoptosis, and selectively eliminates leukemia progenitors.
• Therapeutic efficacy demonstrated in multiple AML models, including MLL-AF9 and patient-derived xenografts.

Conclusions:

• Dual CKIα/CDK7/9 inhibition represents a promising therapeutic strategy for AML.
• The inhibitors selectively target leukemia cells by disrupting SE-driven oncogene addiction.
• This approach offers potential for leukemia cure with preserved hematopoiesis.